Skip to main content
NCBI home page
Biomedical Reports logoLink to Biomedical Reports
. 2014 Jun 16;2(5):713–718. doi: 10.3892/br.2014.296

Association of NQO1 and TNF polymorphisms with Parkinson’s disease: A meta-analysis of 15 genetic association studies

DONGJUN DAI 1,*, PEIPEI LIN 1,*, YUNLIANG WANG 2,*, XINGYU ZHOU 1, JIANMIN TAO 1, DANJIE JIANG 1, HANLIN ZHOU 1, PING RU 1, GUANGHUI PAN 1, JINFENG LI 2, YUZHENG ZHANG 2, HONGLEI YIN 2, SHIWEI DUAN 1,✉
PMCID: PMC4106539  PMID: 25054016

Abstract

Parkinson’s disease (PD) is a neurodegenerative movement d’isorder that affects ~2% of the population aged ≥65 years. NAD(P)H-quinone oxidoreductase 1 (NQO1) and tumor necrosis factor-α (TNF-α) are two important factors in the generation of oxidative stress in PD. The aim of the present study was to assess the association of NQO1 and tumor necrosis factor (TNF) polymorphisms with PD. A meta-analysis was performed that included data from 15 studies comprising 2,858 patients and 2,907 healthy controls. The results showed that TNF-1031 (rs1799964) was significantly associated with PD in the recessive [P=0.0005; odds ratio (OR), 3.19; 95% confidence interval (CI), 1.66–6.13] and additive models (P=0.0006; OR, 3.15; 95% CI, 1.63–3.51). However, there was no significant association in NQO1 C609T (rs1800566) and TNF-308 (rs1800629) with PD. To the best of our knowledge, the present study is the first meta-analysis of NQO1 and TNF polymorphisms with PD demonstrating that TNF-1031 polymorphism may be a risk factor for PD under either the recessive or additive models. However, the meta-analyses did not support the involvement of NQO1 C609T and TNF-308 in the risk of PD.

Keywords: Parkinson’s disease, tumor necrosis factor-308, tumor necrosis factor-1031, meta-analysis, NAD(P)H-quinone oxidoreductase 1 C609T

Introduction

Parkinson’s disease (PD; OMIM: #168600), which is attributed to the death of nigrostriatal dopaminergic neurons, is a neurodegenerative movement disorder that affects ~2% of the population aged ≥65 years. The clinical features of PD, including tremor, rigidity and bradykinesia (1) and other severe complications (2), leading to considerable damage to human body.

PD is a complex disease affected by genetic and environmental factors. Environmental factors comprise of oxidative stress (3), smoking (4) and environmental toxins (5). These environmental risk factors have been found to play an important role in the progression of PD. In addition, genetic predisposition plays a clear role in this complex disease. Previous genetic studies have identified numerous genetic markers of PD (6–8).

Oxidative stress caused by the accumulation of oxidative species is closely associated with PD (9). The quinone intermediates that are derived from dopamine metabolism are pivotal to the generation of oxidative stress. NQO1, which is located on chromosome 16q22.1, encodes NAD(P)H-quinone oxidoreductase 1 (NQO1), which is a detoxification enzyme involved in dopamine metabolism. NQO1 has been found to be expressed in astroglial and endothelial cells in substantia nigra pars compacta (10). Tumor necrosis factor (TNF) is located in the human leukocyte antigen class III region on chromosome 6p21.3 (11). TNF encodes TNF-α, which is one of the principal cytokines involved in promoting inflammation and oxidative stress (12).

A number of case-control studies have been carried out previously to identify the association between PD and the NQO1 and TNF polymorphisms (13–29). There were four positive and four negative studies for the association of the NQO1 C609T polymorphism and PD. There was one positive and six negative studies for the association between the TNF-308 polymorphism and PD, and there were two positive and one negative study between TNF-1031 polymorphism and PD. The inconsistent conclusions may be due to the limited power of each study and difference in ethnicity in these genetic loci.

Meta-analyses are able to enhance the credibility of association studies by combining data from different studies and drawing a more comprehensive conclusion (30). In the present study, a comprehensive meta-analysis was conducted to establish the role of these loci in the risk of PD.

Materials and methods

Data collection

A systematic literature search was performed using online databases [PubMed, WanFang, WeiPu and China National Knowledge Infrastructure (CNKI)], without time and language restriction, and by searching the following keywords: ‘Parkinson NQO1 association or Parkinson NQO1 polymorphism’ and ‘Parkinson TNF association or Parkinson TNF polymorphism’ to collect available studies. The studies were involved when they met the following criteria: i) The study was an original case-control study with assessment of the association between PD and polymorphisms of NQO1 and TNF in humans; ii) it contained sufficient information to infer the odd ratios (ORs) and 95% confidence intervals (CIs); and iii) the genotype distribution of each polymorphism in the controls met the Hardy-Weinberg equilibrium (HWE). All the studies included in the meta-analyses were carefully considered and selected in January 2014. As shown in previous studies (31–34), the following information was precisely extracted or calculated from each study: Genetic locus, first author’s name, year of publication, country, ethnicity, the numbers of cases and controls, control source, HWE for controls, the power of individuals and whether the study had significant association with PD and the power of individuals (Table I).

Table I.

Characteristics of the case-control studies in the present meta-analyses.

Genetic locus Authors Year Country Ethnicity Cases/controls Control source HWE Result Power (Refs.)
NQO1 C609T Harada et al 2001 Japan Asians 111/100 Hospital Yes NS 0.152 (13)
Shao et al 2001 China Asians 126/136 Hospital Yes S 0.179 (14)
Jiang et al 2004 China Asians 274/161 Hospital No S 0.195 (15)
Okada et al 2005 USA Europeans 163/269 Hospital Yes NS 0.188 (16)
Shao et al 2005 China Asians 140/144 Population Yes S 0.117 (17)
Xu et al 2007 China Asians 52/133 Population Yes NS 0.184 (18)
Fong et al 2007 China Asians 149/153 Hospital No NS 0.199 (20)
Punia et al 2011 Indian Asians 339/344 Population Yes S 0.373 (19)
TNF-308 Kruger et al 2000 Germany Europeans 237/177 Population Yes S 0.133 (21)
Ross et al 2004 UK Europeans 90/93 Hospital Yes NS 0.102 (22)
Wahner et al 2007 USA Europeans 289/269 Population Yes NS 0.281 (23)
Wu et al 2007 China Asians 369/326 Hospital Yes NS 0.199 (24)
Bialecka et al 2008 Poland Europeans 316/300 Population Yes NS 0.106 (25)
Du et al 2009 China Asians 114/133 Population Yes NS 0.081 (26)
Pascale et al 2010 Italy Europeans 146/156 Hospital Yes NS 0.184 (27)
TNF-1031 Nishimura et al 2001 Japan Asians 172/157 Hospital Yes S 0.126 (28)
Wu et al 2007 China Asians 369/326 Hospital Yes S 0.180 (24)
Infante et al 2008 Spain Europeans 194/170 Population Yes NS 0.096 (29)
Open in a new tab

HWE, Hardy-Weinberg equilibrium; NQO1, NAD(P)H-quinone oxidoreductase 1; NS, not significant; S, significant; TNF, tumor necrosis factor.

Statistical analysis

The Arlequin program was used to test HWE (35). The power of each study was calculated by the Power and Sample Size Calculation program (36). The statistical heterogeneity across the studies included in the meta-analysis was assessed by Cochran’s Q statistic and I2 tests (37) to determine the type of analysis. In the meta-analysis, the fixed-effects model was used for the studies with minimal to moderate heterogeneity (I2<50%) and the random-effects model was used for the studies with significant heterogeneity (I2≥50%). In addition to the allelic analysis model, the meta-analyses were performed under the dominant, recessive and additive models. Funnel plots were also drawn to observe the potential publication bias. The statistical analyses of the meta-analyses were carried out in Review Manager 5 (The Cochrane Collection, Copenhagen, Denmark) (38).

Results

Data selection

As shown in Fig. 1, nine relevant NQO1 studies and 16 TNF studies were selected from PubMed. In addition, three NQO1 studies and one TNF study from the WanFang literature database, and two NQO1 studies and one TNF study from CNKI were included. Following the removal of the duplicates, two studies with no PD association, nine without genotyping information and two with significant deviation from HWE (P<0.05) in the controls were excluded (Table I). A study was also found from the references in the retrieved literature. Finally, 15 eligible studies (16 stages) (13,14,16–19,21–29) were included in the meta-analyses (Table I).

Figure 1.

Figure 1

Open in a new tab

Flowchart of selection process in the meta-analyses.

Meta-analyses of NQO1 and TNF polymorphisms with PD

As shown in Table II, the meta-analysis of the NQO1 C609T polymorphism included 931 PD patients and 1,126 healthy controls among six studies. The statistical heterogeneity was observed in the meta-analyses of NQO1 C609T (allelic, I2=83%; dominant, I2=88%; recessive, I2=51%; and additive models, I2=83%). The frequency of the NQO1 C609T-C allele in Europeans was 0.788 (HapMap-CEU), which was much higher than that of the Asian population (HapMap-CHB=0.478; HapMap-JPT=0.611). A further analysis showed a difference in ethnicity of the NQO1 C609T polymorphism between Europeans and Asians (Fst=0.103). As a different genotypic distribution existed in the NQO1 C609T polymorphism between Europeans and Asians, further subgroup meta-analyses were performed by ethnicity. There was no significant association observed in NQO1 C609T (P=0.69; OR, 1.07; 95% CI, 0.76–1.50; Table II; Fig. 2), and no significant association was found in other subgroup meta-analyses by genotype and ethnicity (Table II).

Table II.

Meta-analyses of the association between NQO1 C609T, TNF-308 and TNF-1031 and Parkinson’s disease.

Genetic model Cases/Controls Ethnicity No. of studies OR (95% CI) P-value I2 (%) Power
NQO1 C609T
 Overall (T vs. C) 931/1126 Overall 6 1.07 (0.76–1.50) 0.69 83 0.791
768/852 Asians 5 1.15 (0.78–1.70) 0.48 85 0.715
163/269 Europeans 1 0.76 (0.52–1.09) 0.14 NA 0.188
 Dominant (TT/TC vs. CC) 805/990 Overall 5 1.24 (0.67–2.31) 0.49 88 0.771
642/721 Asians 4 1.43 (0.63–3.27) 0.39 90 0.641
163/269 Europeans 1 0.76 (0.50–1.16) 0.20 NA 0.245
 Recessive (TT vs. TC/CC) 805/990 Overall 5 0.77 (0.44–1.34) 0.36 51 0.402
642/721 Asians 4 0.83 (0.47–1.47) 0.53 57 0.381
163/269 Europeans 1 0.23 (0.03–1.90) 0.17 NA 0.077
 Additive (TT vs. CC) 429/574 Overall 5 0.92 (0.32–2.61) 0.87 83 0.356
314/395 Asians 4 1.13 (0.36–3.53) 0.83 87 0.320
115/179 Europeans 1 0.22 (0.03–1.78) 0.15 NA 0.077
TNF-308
 Overall (A vs. G) 1561/1454 Overall 7 1.08 (0.93–1.24) 0.31 28 0.719
1078/995 Europeans 5 1.08 (0.92–1.27) 0.35 5 0.609
483/459 Asians 2 0.79 (0.29–2.18) 0.65 76 0.216
 Dominant (AA/AG vs. GG) 1245/1154 Overall 6 0.96 (0.69–1.31) 0.78 60 0.793
842/752 Europeans 4 0.98 (0.66–1.44) 0.90 64 0.638
403/402 Asians 2 0.77 (0.27–2.22) 0.63 76 0.332
 Recessive (AA vs. AG/GG) 1254/1154 Overall 6 1.34 (0.80–2.23) 0.26 15 0.163
762/695 Europeans 4 1.40 (0.82–2.41) 0.22 32 0.149
483/459 Asians 2 0.88 (0.18–4.40) 0.88 NA 0.062
 Additive (AA vs. GG) 960/896 Overall 6 1.31 (0.78–2.20) 0.31 0 0.163
567/514 Europeans 4 1.36 (0.79–2.35) 0.27 18 0.148
393/382 Asians 2 0.93 (0.19–4.64) 0.93 NA 0.062
TNF-1031
 Overall (C vs. T) 735/653 Overall 3 1.24 (0.85–1.79) 0.26 58 0.383
 Dominant (CC/CT vs. TT) 735/653 Overall 3 1.12 (0.70–1.78) 0.64 62 0.495
 Recessive (CC vs. CT/TT) 735/653 Overall 3 3.19 (1.66–6.13) 0.0005a 0 0.101
 Additive (CC vs. TT) 587/507 Overall 3 3.15 (1.63–1.07) 0.0006a 0 0.101
Open in a new tab
a

P≤0.05.

NQO1, NAD(P)H-quinone oxidoreductase 1; TNF, tumor necrosis factor; OR, odds ratio; CI, confidence interval; NA, not applicable.

Figure 2.

Figure 2

Open in a new tab

Forest plots of NAD(P)H-quinone oxidoreductase 1 (NQO1) and tumor necrosis factor (TNF) polymorphisms with Parkinson’s disease. CI, confidence interval.

Meta-analysis of the TNF-308 polymorphism was involved with 3,122 PD patients and 2,908 healthy controls among seven studies (Table II). No significant heterogeneity was found in the meta-analysis under the allelic model (I2=28%), and no significant association of TNF-308 with PD was observed (P=0.31; OR, 1.08; 95% CI, 0.93–1.24; Table II; Fig. 2). Analysis of the association between TNF-308 with PD in ethnicity and genetic models was performed, but no positive result was found (Table II).

The meta-analysis of the TNF-1031 polymorphism was conducted with 735 PD patients and 653 healthy controls among three studies (Table II). The TNF-1031 polymorphism was shown to be a risk factor of PD in the meta-analyses under the recessive (P=0.0005; OR, 3.19; 95% CI, 1.66–6.13) and additive models (P=0.0006, OR, 3.15; 95% CI, 1.63–6.07), however, there was no significant association in the meta-analysis under the allelic model (P=0.26, OR, 1.24; 95% CI, 0.85–1.79; Table II; Fig. 2). As there were only three studies in the meta-analysis of the TNF-1031 polymorphism, the result of this strong association requires interpreting with caution (Table II). No publication bias was found for all the meta-analyses (Fig. 3).

Figure 3.

Figure 3

Open in a new tab

Funnel plots of NAD(P)H-quinone oxidoreductase 1 (NQO1) C609T, tumor necrosis factor (TNF)-308 and TNF-1031. SE, standard error; OR, odds ratio.

Discussion

To the best of our knowledge, the present study is the first meta-analysis on NQO1 and TNF. The meta-analysis involved 15 studies with 2,858 patients and 2,907 healthy controls. Allelic analysis and genetic models were performed for the meta-analyses and subgroup analyses were also conducted by ethnicity in NQO1 C609T and TNF-308. The power of the study was 0.791 in NQO1 C609T and 0.719 in TNF-308, which were much stronger than each of the original case-control studies (power≤0.373).

There was no significant association observed between NQO1 C609T and PD. The same conclusion was drawn when a further subgroup study by ethnicity was conducted. The result of NQO1 C609T was consistent with three involved studies (13,16,18), whereas it was inconsistent with another three involved studies (14,17,19) that had a stronger power. The present meta-analysis draws a more reliable conclusion than the previous studies. Notably, as there were five Asian studies and only one European study (Table I), the conclusion may have shown a deviation to the Asian population, and the lower power of the European data suggested that larger case-control studies are required.

The meta-analysis also suggested that TNF-308 had no association for PD. This result is consistent with the majority of previous studies (22–27), and only one study presented an opposing conclusion (21). In comparison to the former studies, the meta-analysis showed a stronger power and involved subgroup analyses by genetic models and ethnicity, which allowed for a more stable and comprehensive conclusion.

TNF-1031 was observed to significantly increase the risk of PD in the recessive and additive models (P=0.0005 and P=0.0006, respectively). TNF-1031 is a key polymorphism located in the promoter of TNF that influences the transcriptional regulation of TNF production (39). Among the three studies included in the meta-analysis of TNF-1031, two studies showed that TNF-1031 was associated with an increased risk of PD (24,28). The present meta-analysis may provide novel information for the association between TNF-1031 and PD. However, due to the small power of TNF-1031, the positive result of TNF-1031 should be interpreted with caution.

Certain limitations of the meta-analysis should be considered. Firstly, PD is a complicated disorder influenced by numerous factors, including gender and age differences. The aforementioned information was not provided in the original case-control studies. Thus, a subgroup meta-analysis cannot be performed by gender or age to establish a more credible result. Secondly, there were a number of populations involved in the meta-analyses of NQO1 C609T (Chinese, Japanese, Indian and American populations), TNF-308 (German, Italian, United Kingdom, American, Polish and Chinese populations) and TNF-1031 (Chinese, Japanese and Spanish populations). Future studies in other ethnic populations are required to completely assess the contribution of these polymorphisms to PD. Thirdly, the clinical diagnostic accuracy of PD is only 70% (40). Different diagnostic criteria among the various case-control studies may have an impact on the results of the meta-analyses. Fourthly, there are 1,574 polymorphisms on the NQO1 and TNF loci, respectively. The present meta-analyses only focused on specific polymorphisms, NQO1 (NQO1 C609T) and TNF (TNF-308 and TNF-1031). These findings may not completely represent the overall contribution of NQO1 and TNF to PD.

In conclusion, the results of the present study indicated that TNF-1031 polymorphism may be a risk factor for PD under either the recessive or additive models. However, the meta-analyses did not support the involvement of NQO1 C609T and TNF-308 in the risk of PD.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 31100919 and 81371469), the Natural Science Foundation of Zhejiang Province (grant no. LR13H020003) and the K. C. Wong Magna Fund in Ningbo University and Ningbo Social Development Research Projects (grant no. 2012C50032).

References

  • 1.Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909. doi: 10.1016/s0896-6273(03)00568-3. [DOI] [PubMed] [Google Scholar]
  • 2.Arora A, Fletcher P. Problem based review: a patient with Parkinson’s disease. Acute Med. 2013;12:246–250. [PubMed] [Google Scholar]
  • 3.Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 1999;22:123–144. doi: 10.1146/annurev.neuro.22.1.123. [DOI] [PubMed] [Google Scholar]
  • 4.Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;26(Suppl 1):S1–S58. doi: 10.1007/s10654-011-9581-6. [DOI] [PubMed] [Google Scholar]
  • 5.Vaglini F, Viaggi C, Piro V, et al. Acetaldehyde and parkinsonism: role of CYP450 2E1. Front Behav Neurosci. 2013;7:71. doi: 10.3389/fnbeh.2013.00071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lill CM, Roehr JT, McQueen MB, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet. 2012;8:e1002548. doi: 10.1371/journal.pgen.1002548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.McInerney-Leo A, Hadley DW, Gwinn-Hardy K, Hardy J. Genetic testing in Parkinson’s disease. Mov Disord. 2005;20:1–10. doi: 10.1002/mds.20316. [DOI] [PubMed] [Google Scholar]
  • 8.Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol. 2010;23:228–242. doi: 10.1177/0891988710383572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013;3:461–491. doi: 10.3233/JPD-130230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.van Muiswinkel FL, de Vos RA, Bol JG, et al. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging. 2004;25:1253–1262. doi: 10.1016/j.neurobiolaging.2003.12.010. [DOI] [PubMed] [Google Scholar]
  • 11.Kamoun M, Chelbi H, Houman MH, Lacheb J, Hamzaoui K. Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet’s disease. Hum Immunol. 2007;68:201–205. doi: 10.1016/j.humimm.2006.12.006. [DOI] [PubMed] [Google Scholar]
  • 12.Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999;100:34–41. doi: 10.1111/j.1600-0404.1999.tb00721.x. [DOI] [PubMed] [Google Scholar]
  • 13.Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson’s disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun. 2001;288:887–892. doi: 10.1006/bbrc.2001.5868. [DOI] [PubMed] [Google Scholar]
  • 14.Shao M, Liu Z, Tao E, Chen B. Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene in Parkinson’s disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2001;18:122–124. (In Chinese) [PubMed] [Google Scholar]
  • 15.Jiang XH, Yang H, Yang JF, Wang HT, Xu QY, Chen B. A study on the relationship between polymorphism of human NAD(P)H: quinone oxidoreductase and Parkinson’s disease in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004;21:120–123. (In Chinese) [PubMed] [Google Scholar]
  • 16.Okada S, Farin FM, Stapleton P, et al. No associations between Parkinson’s disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes. Neurosci Lett. 2005;375:178–180. doi: 10.1016/j.neulet.2004.11.009. [DOI] [PubMed] [Google Scholar]
  • 17.Shao M, Liu ZL, Tao EX, Chen B. Correlation between the genetic polymorphism of dopamine metabolic enzymes and the genetic susceptibility of Parkinson’s disease. Chin J Gerontol. 2005;25:743–745. [Google Scholar]
  • 18.Xu H, Du W, Sun Z, et al. Genetic analysis of P2X7 C489T and NQO1 C609T polymorphisms and susceptibility of primary Parkinson’s disease. Chin J Exp Surg. 2007;24:1310–1312. [Google Scholar]
  • 19.Punia S, Das M, Behari M, et al. Leads from xenobiotic metabolism genes for Parkinson’s disease among north Indians. Pharmacogenet Genomics. 2011;21:790–797. doi: 10.1097/FPC.0b013e32834bcd74. [DOI] [PubMed] [Google Scholar]
  • 20.Fong CS, Wu RM, Shieh JC, et al. Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson’s disease. Clin Chim Acta. 2007;378:136–141. doi: 10.1016/j.cca.2006.11.006. [DOI] [PubMed] [Google Scholar]
  • 21.Krüger R, Hardt C, Tschentscher F, et al. Genetic analysis of immunomodulating factors in sporadic Parkinson’s disease. J Neural Transm. 2000;107:553–562. doi: 10.1007/s007020070078. [DOI] [PubMed] [Google Scholar]
  • 22.Ross OA, O’Neill C, Rea IM, et al. Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson’s disease in the Irish. Hum Immunol. 2004;65:340–346. doi: 10.1016/j.humimm.2004.01.015. [DOI] [PubMed] [Google Scholar]
  • 23.Wahner AD, Sinsheimer JS, Bronstein JM, Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol. 2007;64:836–840. doi: 10.1001/archneur.64.6.836. [DOI] [PubMed] [Google Scholar]
  • 24.Wu YR, Feng IH, Lyu RK, et al. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:300–304. doi: 10.1002/ajmg.b.30435. [DOI] [PubMed] [Google Scholar]
  • 25.Bialecka M, Klodowska-Duda G, Kurzawski M, et al. Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson’s disease patients. Parkinsonism Relat Disord. 2008;14:636–640. doi: 10.1016/j.parkreldis.2008.02.001. [DOI] [PubMed] [Google Scholar]
  • 26.Du WD, Tang XF, Tang HY, et al. Tumor necrosis factor alpha (TNFα) rs1800629 and lymphotoxin alpha (LTA) rs909253 might not be potential susceptibility locus leading to Chinese sporadic Parkinson’s disease. Chin J Dis Control Prev. 2009;13:33–38. [Google Scholar]
  • 27.Pascale E, Passarelli E, Purcaro C, et al. Lack of association between IL-1β, TNF-α, and IL-10 gene polymorphisms and sporadic Parkinson’s disease in an Italian cohort. Acta Neurol Scand. 2011;124:176–181. doi: 10.1111/j.1600-0404.2010.01441.x. [DOI] [PubMed] [Google Scholar]
  • 28.Nishimura M, Mizuta I, Mizuta E, et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson’s disease. Neurosci Lett. 2001;311:1–4. doi: 10.1016/s0304-3940(01)02111-5. [DOI] [PubMed] [Google Scholar]
  • 29.Infante J, García-Gorostiaga I, Sánchez-Juan P, et al. Inflammation-related genes and the risk of Parkinson’s disease: a multilocus approach. Eur J Neurol. 2008;15:431–433. doi: 10.1111/j.1468-1331.2008.02092.x. [DOI] [PubMed] [Google Scholar]
  • 30.Zintzaras E, Lau J. Trends in meta-analysis of genetic association studies. J Hum Genet. 2008;53:1–9. doi: 10.1007/s10038-007-0223-5. [DOI] [PubMed] [Google Scholar]
  • 31.Xu X, Wang Y, Wang L, et al. Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer’s disease. PloS One. 2013;8:e73129. doi: 10.1371/journal.pone.0073129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Yu X, Huang Y, Li C, Yang H, Lu C, Duan S. Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies. Tumour Biol. 2014;35:1973–1983. doi: 10.1007/s13277-013-1263-4. [DOI] [PubMed] [Google Scholar]
  • 33.Ye H, Li X, Wang L, et al. Genetic associations with coronary heart disease: meta-analyses of 12 candidate genetic variants. Gene. 2013;531:71–77. doi: 10.1016/j.gene.2013.07.029. [DOI] [PubMed] [Google Scholar]
  • 34.Tang L, Wang L, Liao Q, et al. Genetic associations with diabetes: meta-analyses of 10 candidate polymorphisms. PloS One. 2013;8:e70301. doi: 10.1371/journal.pone.0070301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online. 2007;1:47–50. [PMC free article] [PubMed] [Google Scholar]
  • 36.Gibson E, Fenster A, Ward AD. The impact of registration accuracy on imaging validation study design: A novel statistical power calculation. Med Image Anal. 2013;17:805–815. doi: 10.1016/j.media.2013.04.008. [DOI] [PubMed] [Google Scholar]
  • 37.Coory MD. Comment on: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2010;39:932–933. doi: 10.1093/ije/dyp157. [DOI] [PubMed] [Google Scholar]
  • 38.Kawalec P, Mikrut A, Wiśniewska N, Pilc A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2013;32:1415–1424. doi: 10.1007/s10067-013-2329-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Higuchi T, Seki N, Kamizono S, et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998;51:605–612. doi: 10.1111/j.1399-0039.1998.tb03002.x. [DOI] [PubMed] [Google Scholar]
  • 40.Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biomedical Reports are provided here courtesy of Spandidos Publications

RESOURCES